No abstract

No abstract

No abstract

Vaccines are one of the most important tools available to prevent and reduce the incidence of infectious diseases in cattle. Despite their availability and widespread use to combat many important pathogens impacting cattle, several of these products demonstrate variable efficacy and safety in the field, require multiple doses, or are unstable under field conditions. Recently, nanoparticle-based vaccine platforms (nanovaccines) have emerged as promising alternatives to more traditional vaccine platforms. In particular, polymer-based nanovaccines provide sustained release of antigen payloads, stabilize such payloads, and induce enhanced antibod- and cell-mediated immune responses, both systemically and locally. To improve vaccine administrative strategies and efficacy, they can be formulated to contain multiple antigenic payloads and have the ability to protect fragile proteins from degradation. Nanovaccines are also stable at room temperature, minimizing the need for cold chain storage. Nanoparticle platforms can be synthesized for targeted delivery through intranasal, aerosol, or oral administration to induce desired mucosal immunity. In recent years, several nanovaccine platforms have emerged, based on biodegradable and biocompatible polymers, liposomes, and virus-like particles. While most nanovaccine candidates have not yet advanced beyond testing in rodent models, a growing number have shown promise for use against cattle infectious diseases. This review will highlight recent advancements in polymeric nanovaccine development and the mechanisms by which nanovaccines may interact with the bovine immune system. We will also discuss the positive implications of nanovaccines use for combating several important viral and bacterial disease syndromes and consider important future directions for nanovaccine development in beef and dairy cattle.

No abstract

-induced immune suppression is a major obstacle faced by the host for controlling infections. impairment of antigen-specific T-cell responses is achieved through inhibiting the proliferation of peripheral blood mononuclear cells (PBMCs). This impairment may contribute to the persistence of infection in various sites, including lungs, and its systemic spread to various organs such as joints, with the underlying mechanisms remaining elusive. Here, we elucidated the role of the immune-inhibitory receptor programmed death 1 (PD-1) and its ligand (PD-L1) in infection. Flow cytometry (FCM) analyses revealed an upregulation of PD-L1 expression on tracheal and lung epithelial cell lines after infection. In addition, we found increased PD-L1 expression on purified lung lavage macrophages following infection by FCM and determined its localization by immunofluorescence analysis comparing infected and control lung tissue sections. Moreover, infection increased the expression of the PD-1 receptor on total PBMCs and in gated CD4 and CD8 T-cell subpopulations. We demonstrated that infection induced a significant decrease in CD4 PD-1 and CD8 PD-1 subsets with intermediate PD-1 expression, which functioned as progenitor pools giving rise to CD4 PD-1 and CD8 PD-1 subsets with high PD-1 expression levels. We blocked PD-1 receptors on PBMCs using anti-PD-1 antibody at the beginning of infection, leading to a significant restoration of the proliferation of PBMCs. Taken together, our data indicate a significant involvement of the PD-1/PD-L1 inhibitory pathway during infection and its associated immune exhaustion, culminating in impaired host immune responses.

No abstract

Innate immunity, initially thought to lack immunological memory, has been shown to have the capacity to be trained or to mount a heightened immune response towards an unrelated second challenge. The Bacillus Calmette Guerin vaccine, administered to prevent human and bovine tuberculosis, is one treatment that can induce innate immune memory. Here we evaluated the efficacy of BCG-induced innate training on the outcome of a respiratory virus challenge in pre-weaned calves. Groups of calves were given BCG Danish strain subcutaneously (or PBS as control). PBMCs and CD14+ monocytes were re-stimulated in-vitro with E. coli LPS (1μg/mL) or Pam3CSK4 (10μg/mL) at 2- and 4-weeks post-BCG respectively, and pro-inflammatory cytokine production was measured by ELISA. Calves were challenged via aerosol inoculation with BRSV at five weeks post-BCG. PBMCs from BCG calves showed enhanced IL-1b production upon in-vitro stimulation with LPS, and CD14+ monocytes from BCG calves showed increased IL-1b and IL-6 secretion. Alveolar macrophages from BCG calves showed enhanced cytokine production when re-stimulated with LPS. No significant changes were observed in clinical scores or viral burden between groups post BRSV challenge. Subcutaneous BCG administration can train bovine innate immune cells to exhibit a “memory-like” phenotype. Current efforts are focused on the characterization of epigenetic reprogramming in trained innate immune cells. Supported by grants from USDA, NIFA. R01 HD099104-01